Medicines Australia says maintains its longstanding concern over the conditional nature of PBAC recommendations and that it could be considered in the upcoming health technology assessment review.
MA: HTA review could consider new non-PBAC pricing body
January 20, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast -
New partnership aims to strengthen local cell and gene manufacturing capability
October 16, 2025 - - Australian Biotech -
Vertex announces New Zealand registration of next-generation cystic fibrosis treatment
October 16, 2025 - - Latest News -
Lilly’s oral GLP-1 therapy delivers strong results in late-stage diabetes trials
October 16, 2025 - - Latest News -
NDIS participant numbers and spending continue growth trajectory in latest quarterly data
October 15, 2025 - - Other Health -
Key Pharmaceuticals builds on a 40-year legacy to support frontline health
October 15, 2025 - - Latest News